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We studied binding and growth inhibitory properties of different glycosaminoglycans i  growing and differentiated BC3H-I muscle cells. Heparin 
(10 pg/ml) and heparan sulfate (10 ,ug/ml) significantly inhibited DNA synthesis in growing and differentiated cells, as monitored by PH]thymidine 
incorporation. Binding of heparin to BC3H-1 cells was specific and time-dependent. Heparan sulfate was the only glycosaminoglycan ble to dis- 
place PH]heparin (I&,, 3.2 x lo-’ M), although it was lo-fold less effective than heparin itself (IC,,, 3.6 x lo-* M). Scatchard analysis revealed 
the existence of high-alBnity heparin binding sites (K,,, 5 x lo-* M). Furthermore, heparin inhibited serum-induced stimulation of inositol lipid 
turnover. Taken together, these results indicate that heparin inhibits BC3H-1 cell growth by interacting with the cell surface, possibly disrupting 
the flow of growth factor-related mitogenic signalling. 
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1. INTRODUCTION 
Several studies in vivo and in vitro showed that 
heparin inhibits proliferation of vascular smooth mus- 
cle cells [l-3]. The molecular mechanism(s) involved in 
this effect are not known as yet; some studies do not 
support the possibility of direct interaction between 
heparin and growth factors [l]. Recent evidence, on the 
other hand, suggests that the effects of heparin on 
vascular smooth muscle cells are receptor-mediated [4]. 
A heparin-binding protein of 78 Kd from bovine uteri, 
thought to be involved in the inhibition of vascular 
smooth muscle cell proliferation, has been described 
[5]. Interestingly, the antiproliferative effect of heparin 
on vascular smooth muscle cells is reversed by EGF, 
but not by PDGF, IGF-1 or thrombin [a]. In this case, 
heparin, acting intracellularly, seems to cause a 
decrease of EGF receptors [6]. In BC3H-1 cells EGF, 
acting in synergism with FGF, is reported to induce cell 
growth [7]. 
The effect of heparin on cell growth differs greatly in 
varying experimental conditions. Endothelial cells pro- 
vide a good example of this; heparin stimulates en- 
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dothelial cell proliferation by interacting with, and 
potentiating the effect of ECGF and a-FGF [8,9]. In 
human umbilical vein endothelial (HUVE) cells, 
heparin fails to stimulate cell growth in the absence of 
growth factors [lo]. In human omental microvascular 
endothelial (HOME) cells, heparin inhibits the pro- 
liferation of exponentially growing cells, but not that of 
serum-deprived cultures [ 111. 
Given such a complexity, we decided to study the ef- 
fects of heparin in BC3H-1 cells, i.e. a cell line that ex- 
hibits different traits according to the stage of 
differentiation [12]. The clonal cell line BC3H-1 was 
obtained by Shubert et al. from a nitrosoethylurea- 
induced tumor in the C3H mouse [ 131. These cells grow 
logarithmically in culture and are able to differentiate 
toward a more mature muscle phenotype after being 
serum-starved and growth-arrested. The process of dif- 
ferentiation does not involve cell fusion. Ultrastruc- 
tural features typical of smooth muscle cells have been 
observed by electron microscopy. Among other traits 
indicative of smooth muscle origin are expression of the 
muscle isoform of creatine phosphokinase, myokinase, 
and smooth muscle cu-actin [ 13-161. A recent study, 
however, points out that differentiated BC3H-1 cells 
express sarcomeric muscle-specific ontractile protein 
genes, thus resembling skeletal myoblasts that are 
defective for commitment to terminal differentiation 
WI. 
Therefore, we decided to characterize the response of 
this clonal cell line to heparin, and related GAGS, tak- 
ing into consideration growing and differentiated cells. 
Here we demonstrate that heparin and heparan sulfate, 
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but not other GAGS, bind to, and inhibit the growth of 
BC3H-1 cells in culture, independently of the stage of 
differentiation. Fu~hermore, we describe the in- 
hibitory effect of heparin on serum-induced inositol 
lipid turnover, thus suggesting that heparin might 
disrupt the normal flow of mitogenic signalling at the 
cell surface. 
2. MATERIALS AND METHODS 
[‘H]Heparin (400 &i/mg, average molecular mass 15 kDa), and 
[3H]thymidine (82.2 Ci/mmol) were purchased from New England 
Nuclear. Heparin EP 756 from bovine intestinal mucosa (average 
molecular mass 12.9 kDa; 150 U/mg), very low molecular weight 
heparin obtained from peroxidative cleavage of bovine heparin 
(VLMW-he~rin 1027/45 GP; average molecular mass 2.1 kDa), and 
dermatan sulfate OP 435, were kindly provided by Opocrin Research 
Laboratories, Modena, Italy. Heparan sulfate (from bovine lung) 
was donated by Professor Cifonelli (Department of Pediatrics, 
University of Chicago, USA). Hyahtronic acid (from human um- 
bilical cord), chondroitin sulfate C (from shark cartilage), and chon- 
droitin sulfate A were from Sigma Chemical. Sephacryl S-200 was 
from Pharmacia. 
The BC3H-1 cell line was obtained from American Type Cell 
Cultures (Rockville, MD, USA). The cells for each experiment were 
plated at an initial cell density of 4000-5000 cells/cm’, and cultured 
at 37°C in DMEM containing 10% fetal calf serum forthe length of 
time indicated in each experiment. The medium was not changed ur- 
ing the course of the experiment. Binding experiments were perform- 
ed on fully ~fferentiat~ cells, i.e. 5 days after confluence. 
[3H]Thymidine incorporation was studied in cells two days before 
confluence, at confluence, and for the next 6 days. Briefly, 
[3H]thymidine (4 &i/ml) was added to the cultures for 1 h. At the 
end of the incubation period, the medium was removed and the 
radioactivity incorporated into TCA-precipitable material was 
counted. The antiproliferative ffect of differential GAGS on grow- 
ing BC3H-1 cells was determined by adding 10 pglml of each com- 
pound 24 h before pulse labelling. Each experiment was performed 
in quadruplicate. The protein concentration was determined by the 
Bradford method, using BSA as standard [17]. 
Binding experiments were performed on BC3H-1 cells cultured in 
17-mm plates. Five days after confluence, cultures were washed with 
cold PBS and precooled at 4% for 30 min. Binding experiments were 
initiated by adding PBS (1 ml) containing 0.1% human serum 
albumin, increasing concentrations of [3H]heparin (7.5-30 nM) 
without unlabelled heparin, and t3H]heparhr (30 nM) with increasing 
concentrations of unlabelled ligand (10-100 nM). Non-specific bin- 
ding was determined in the presence of lOO-fold excess of unlabelled 
ligand. Cells were incubated at 4’C for 2 h. The reaction was stopped 
by removing the incubation medium; cells were collected from the 
dishes onto GFfC filters ~hatman) and washed 5 times with cold 
PBS (5 ml). Filters were dried and counted for 3H-radioactivity in a 
liquid scintillation counter. The unspecific binding of i3H]heparin to 
filters was negligible. 
The effect of heparin on serum-induced inositol lipid turnover was 
monitored as accumulation of [“Hlinositol phosphates in cells 
prelabelled with [3H]myo-inositol (10 &i/ml) for 48 h. Heparin was 
added either during labelling (24 or 1 h before the expe~ment), or 
concomit~~y with serum. At the end of incubation, cultures were 
washed extensively to remove unincorporated [3H]myo-inositol and, 
when present, heparin added 24 or 1 h earlier. Cultures were 
stimulated in the presence of lithium (10 mM) in order to favor the 
accumulation of water-soluble inositol phosphates. The reaction was 
terminated by adding ice-cold methanol, and inositol phosphates 
were extracted and separated as described [18]. Total inositol 
phosphates were eluted from Dowex AG 1 x 8 columns (Bio-Rad) 
with 1.2 M ammonium formate/O.l M formic acid. 
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Fig. 1. Inhibitory effect of heparin on [‘Hlthymidine incorporation 
in BC3H-1 cells. BC3H-1 cells were grown in DMEM supplemented 
with 10% fetal calf serum. 24 h before the pulse (1 h) labelling with 
]‘H]thymidine, cells were incubated with regular DMEM (100 pi; 
solid bars), or with heparin-con~ning DMEM (10 hg/rnl per plate; 
hatched bars). Measurements were performed on cell cultures 2 days 
before confluence (-2), and at the indicated days after confluence. 
Results are expressed as [‘H]thymidine incorporation and are the 
means f SE of 4 determinations for each point. 
3. RESULTS 
The effect of heparin on BC3H-1 cell growth at dif- 
ferent stages of differentiation is shown in Fig. 1. In- 
corporation of [3H]thymidine was drastically reduced 
when cells reached confluence. Complete inhibition of 
thymidine i~~o~ration, however, occurred 4 days 
after confluence. Heparin (10 &g/ml) caused 30-50% 
inhibition of [3H]thymidine incorporation (Fig. 1). The 
antiproliferative effect was independent of the stage of 
differentiation, since it was evident in growing as well 
as in differentiating cells, Since BC3H-1 cells exhibit 
smooth or skeletal muscle cell characteristics according 
to the stage of differentiation [12], it can be concluded 
that the inhibitory effect of heparin is unaffected by the 
process of differentiation, or by the phenotypic traits 
of the cells. 
In order to ascertain whether the effect of heparin 
was specific, we compared the effect of heparin to that 
of other GAGS on BC3H-1 cell growth (Table I). 
Heparin and heparan sulfate were the only GAGS able 
Table I 
Effect of different glyco~~o~ycans on ~3H]~ymidine 
incorporation in BC3H-1 cells 
Addition @IO inhibition 
None 0 
Heparin EP 756 30 -50 
Heparan sulfate 25 -40 
Hyaluronic acid 0 -1 
Chondroitin sulfate C -l.l- 0 
Dermatan sulfate OP 435 1 - 2.5 
VLMW-heparin 1027145 0 -2 
% inhibition was calculated according to this formula: (1 - dpm of 
[‘H]thymidine in treated cells/dpm of [3HJthymidine in control 
cells) x 100. Values represent he range of i~bition observed in 3 
experiments, each performed in quadruplicate 
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Fig. 2. Specificity of [“Hlheparin binding to BC3H-1 cells. Fully 
differentiated BC3H-1 cells were incubated for 2 h at 4°C with 
[‘Hlheparin (4.0 x 10’ dpm/ml per plate) in the absence (A), or in 
the presence of: 50,cg/ml per plate of heparin EP 756 (B); 
chondroitin sulfate A (C); hyaluronic acid (D); chondroitin sulfate C 
(E); dermatan sulfate OP 435 (F); heparan sulfate (G); very low 
molecular weight heparin OP 1027/45 (H). Results are expressed as 
% of [‘Hlheparin bound to cells, and are means f SE of triplicate 
samples from an experiment representative of 3 others which gave 
identical qualitative results. 
to inhibit cell proliferation. Identical concentrations of 
VLMW-heparin (1027/45 OP) and heparin-unrelated 
GAGS were completely ineffective. 
The time course of [3H]heparin binding to BC3H-1 
cells at 4°C was essentially the same in growing, con- 
fluent, and postconfluent cultures (not shown). 
Specificity of [‘Hlheparin (30 nM) binding to BC3H-1 
cells was determined by incubating the cultures with 
IOO-fold excess of the following unlabelled compounds: 
heparin EP 756; VLMW-heparin 1027/45 OP; 
hyaluronic acid; heparan sulfate; dermatan sulfate OP 
435; chondroitin sulfate A and C (Fig. 2). Heparin bin- 
ding was inhibited by lOO-fold excess of unlabelled 
heparin EP 756, but not by lOO-fold excess of heparin- 
unrelated GAGS. Heparan sulfate was the only GAG 
able to compete for the major portion of specific 
[3H]heparin binding. Fig. 3A shows that the calculated 
I& for heparin was 3.6 x lo-* M, whereas the ICSO 
for heparan sulfate was 3.2 x lo-’ M. Scatchard 
analysis of data (Fig. 3B) indicated a single class of 
.Ol .1 1 10 100 1000 
pg/ml 
high-affinity binding sites with a & value of 5.0 x 
lo-* M. 
A major question about the antiproliferative effect 
of heparin refers to whether heparin acts extra- or in- 
tracellularly. In order to help clarify this point, we 
studied the effect of heparin on serum-induced inositol 
lipid metabolism. Serum-starved (4 days after con- 
fluence) BC3H-1 cells were prelabelled with [‘H]myo- 
inositol and stimulated with serum. Phosphoinositide 
metabolism was monitored as the accumulation of in- 
ositol phosphates. In order to eliminate errors due to 
variability in cell number or labelling efficiency as dif- 
ferentiation proceeded, we took the ratio of counts in 
inositol phosphates to the total counts in all labelled 
phospholipids. Previous studies demonstrated that this 
procedure of normalization is accurate and reliable in 
a variety of experimental conditions [19-211. We found 
that heparin did not affect the basal rate of inositol 
lipid turnover, either when administered uring the in- 
cubation period with [3H]myo-inositol, or just before 
the assay (not shown). It seems therefore that heparin 
does not interact per se with the inositol lipid signalling 
machinery. Heparin, however, significantly inhibited 
serum-induced inositol phosphate formation when ad- 
ministered concomitantly with serum (Fig. 4). This ef- 
fect was strictly related to the binding properties of 
heparin, since VLMW-heparin and chondroitin sulfate 
(that did not displace heparin from the cell surface, see 
Fig. 2) did not affect serum-stimulated inositol lipid 
metabolism (not shown). 
4. DISCUSSION 
The results presented in this paper indicate that 
heparin and heparin-like GAGS specifically bind to 
BC3H-1 cells and inhibit proliferation independently of 
the stage of cell differentiation. VLMW-heparin and 
other GAGS unrelated to heparin failed to show these 
effects. These results suggest hat the GAG molecular 
weight and sulfatation degree are important in deter- 
Kd q 50 nmolll 
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Fig. 3. Displacement of [“Hlheparin and Scatchard analysis of [‘Hlheparin bound to BC3H-1 cells. (A) BC3H-1 cells were incubated for 2 h at 
4°C with [“Hlheparin alone, or in the presence of increasing concentrations of unlabelled compounds. Results are expressed as Vo of bound 
[“Hlheparin and are means of triplicate samples from an experiment representative of 3 others which gave identical qualitative results. (B) 
Scatchard analysis. Each point is the mean of quadruplicate samples. 
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Fig. 4. Effect of heparin on serum-induce inositol lipid metabolism. 
Serum-starved iff~entiating BC3H-1 cells (4 days after confluence 
at the time of the experiment), were preincubated for 48 h with 
[3H]myo-inositol (10 ,&i/ml). Cells were then stimulated with serum 
(lOqo), in the presence or in the absence of heparin (IO/g/ml per 
plate; HP). [3H]Inositol phosphates were separated by anion 
exchange chromatography. Results, expressed as the radioactivity 
recovered in the total inositol phosphate fraction (dpm/lOs dpm in 
total inositol phospholipids) are means & SE of 3 experiments. 
mining the ability to bind to the cell surface. Con- 
sistently, heparan sulfate, although active, was less 
efficient than heparin, whereas VL~W-heparin was 
unable to compete for heparin binding. 
In order to assess the m~h~ism(s) underlying the 
antiproliferative effect of heparin, we studied the turn- 
over of inositol lipids, a major mitogenic signalling 
pathway [20,21]. Heparin, administered either during 
labelling or just before the assay, did not affect the 
basal rate of inositol lipid metabolism, thus suggesting 
that it does not interfere with intracellular GTP- 
binding protein(s) and/or enzymes involved in 
phosphoinositide synthesis and degradation. Heparin, 
however, significantly inhibited serum-induced inositol 
phosphate formation. This effect, just as the i~ibition 
of growth, was strictly related to heparin binding to the 
cell surface; consistently, VLMW-heparin and chon- 
droitin sulfate failed to show any effect on inositol lipid 
turnover and cell proliferation. From the data discuss- 
ed here, it is proposable that heparin, byselectively bin- 
ding in the proximity of certain areas of the cell 
surface, might interfere with growth factor/receptor 
coupling, thus disrupting the flow of mitogenic signall- 
ing from the surface to the nucleus. An interaction bet- 
ween heparin and growth factors has been proposed to 
explain some effects of heparin on endothelial cell 
growth [22,23]. The matter, however, is far from being 
clear, since heparin enhances the effect of ECGF and 
a-FGF [9], but inhibits proliferation of exponentially 
growing HOME cells [I I]. 
Additionally, heparin might act intracellularly after 
being taken up by vascular smooth muscle cells [24,25]. 
A putative target of the intracellular action of heparin 
is the phosphoinositide-related calcium signalling. In 
vascular smooth muscle cells, heparin inhibits inositol 
trisphosphate-dependent, but not guanine nucleotide- 
dependent intracellular calcium mobilization 1261. 
These findings were confirmed by a recent report 
demonstrating that heparin inhibits inositol 
140 
trisphosphate-dependent calcium release in 
permeabilized smooth muscle cells [27]. The extra- and 
intracellular action of heparin might be interconnected, 
as it has been proposed that heparin-induced ecrease 
of EGF receptor number is a consequence of heparin 
acting inside the cell [6]. Most likely, binding to the cell 
surface is a necessary prerequisite for heparin inter- 
nalization. Therefore, heparin might exert a dual ac- 
tion: at the cell surface, interacting with growth factors 
and/or their receptors; inside the cell, affecting 
mitogenic signalling pathways. Another mechanism 
might be related to the heparin effect on synthesis and 
processing of extracellular matrix proteins secreted by 
vascular smooth muscle cells [28-301. Further studies 
are in progress to characterize in detail the molecular 
mechanism(s) underlying the antiproliferative effect of 
heparin. 
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